17 Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$846K Buy
705
+7
+1% +$7.15K 0.38% 85
2026
Q1
$642K Buy
698
+505
+262% +$512K 0.33% 100
2025
Q4
$207K Buy
+193
New +$185K 0.11% 155

Other funds holding LLY

17 Capital Partners's LLY Position: Q2 2026 in Review

17 Capital Partners increased its Eli Lilly (LLY) stake by 1% in Q2 2026, buying an estimated $7.15K and bringing the position to 705 shares worth $846K. The position accounts for 0.38% of the portfolio, ranked #85.

17 Capital Partners first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • 17 Capital Partners held 705 shares of Eli Lilly worth $846K as of Q2 2026.
  • 17 Capital Partners bought 7 Eli Lilly shares in Q2 2026, an estimated $7.15K.
  • Eli Lilly made up 0.38% of 17 Capital Partners's portfolio in Q2 2026, its #85 holding.
  • 17 Capital Partners first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
  • 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on 17 Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.